Jake Jorgovan

JANUARY 30, 2024

The Biopharma industry is always evolving. However, thought leaders in the Biopharma industry offer innovative insights and strategic direction. You're on the right page to find these experts; we’ll discuss Biopharma's top 12 thought leaders, highlighting their unique expertise and what they can teach you. Let’s dive in.

Biopharma 130

Biopharma Life science Biotech Biopharmaceuticals 130

Frost & Sullivan

JUNE 24, 2024

The sessions of the American Society of Clinical Oncology ( ASCO ) 2024 conference focused on this year’s theme – The Art and Science of Cancer Care: From comfort to cure. Merck and Moderna officially disclosed the three-year results from a phase IIb study of their collaborative cancer vaccine for resected melanoma in ASCO.

Biopharmaceuticals 52

Biopharmaceuticals Biopharma Collaboration Ecosystems 52

Frost & Sullivan

AUGUST 29, 2024

However, the pharma/biopharma industry overall shows stagnant R&D activity. growth from 2023 to 2024. Conversely, small-to-mid, and emerging biopharma players, with 1 or 2 molecules in the pipeline, contribute over 16%. increase from 2022. Total R&D expenditure is approximately $276.81 billion, with a modest 2.5%

Biopharma 52

Biopharma Biotechnology Contract research organization Utilities 52

Frost & Sullivan

MARCH 22, 2024

However, the pharma/biopharma industry shows overall stagnant R&D activity. growth from 2023 to 2024. What is driving transformation in the pharma industry? Small-to-mid and emerging biopharma players contribute over 16%. increase from 2022. Total R&D expenditure is approximately $276.81 billion, with a modest 2.5%

Biopharma 52

Biopharma Ecosystems Biotech Contract research organization 52

Frost & Sullivan

APRIL 3, 2024

The Drug, Chemical & Associated Technologies Association (DCAT) 2024 event held in New York City on March 18-21 showcased product and technology innovations and capabilities presentations by member companies. in January 2024 further enhanced its portfolio of complex drug-device combination products.

Biopharmaceuticals 59

Biopharmaceuticals Biopharma Biotechnology Life science 59

Frost & Sullivan

MARCH 16, 2025

The global proteomics industry is poised for significant expansion between 2024 and 2030, driven by advances in research and pharmaceutical applications. Collaborations with academic institutions and clinical research centers will further drive innovation and expand market opportunities. of Competitors 80, with revenue greater than $1.0

Biopharma 52

Biopharma Strategic alliances Strategic partnership Ecosystems 52

Frost & Sullivan

APRIL 2, 2025

As pharmaceutical innovation continues to reshape the industry, key focuses at DCAT Week 2025 included manufacturing capacity expansion, supply chain resilience, digital transformation, and strategic collaborations. trillion in 2024, is expected to grow at a 7% CAGR through 2030.

Biopharma 52

Biopharma Life science Contract research organization Strategic partnership 52